Skip to content

Study · Non-randomized trial · n = 17 · 1986

2 results

A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis.

Naylor GJ, Martin B, Hopwood SE, Watson Y

Biological psychiatry1 Aug 1986Cited by 72 (Europe PMC)

PMID3091097 (opens in a new tab)DOI10.1016/0006-3223(86)90265-9 (opens in a new tab)PepBankPUB-03091097
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In bipolar manic-depressive patients maintained on lithium, depression was significantly lower during methylene blue 300 mg/day than during 15 mg/day.

    In plain wordsPatients maintained on lithium were less depressed with methylene blue 300 mg/day than with 15 mg/day.

    Peptide
    Methylene blue
    Outcome
    DecreaseDepressive symptoms
    Study

    n = 17

    Comparator
    Methylene blue 15 mg/day
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    300 mg/day · 1 year at 300 mg/day (2-year crossover trial)As given in this study (human).

    Source sentences

    Summary
    During the year the patients were treated with methylene blue at 300 mg/day, they were significantly less depressed than during the year on 15 mg/day.
    3 context sentences
    Summary · context
    A 2-year prophylactic trial was carried out in 31 bipolar manic-depressive subjects, comparing 300 mg/day methylene blue on a double-blind crossover basis with 15 mg/day.
    Summary · context
    All patients were also maintained on lithium.
    Summary · context
    Seventeen patients completed the 2-year trial.
  2. 02HumanNon-randomized trialEfficacy outcome

    In bipolar manic-depressive patients maintained on lithium, manic symptom severity did not differ significantly between methylene blue 300 mg/day and 15 mg/day.

    In plain wordsPatients maintained on lithium had no significant difference in manic symptoms between methylene blue 300 mg/day and 15 mg/day.

    Peptide
    Methylene blue
    Outcome
    No significant changeManic symptom severity
    Study

    n = 17

    Comparator
    Methylene blue 15 mg/day
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    300 mg/day · 1 year at 300 mg/day (2-year crossover trial)As given in this study (human).

    Source sentences

    Summary
    No significant difference in the severity of manic symptoms was shown.
    4 context sentences
    Summary · context
    During the year the patients were treated with methylene blue at 300 mg/day, they were significantly less depressed than during the year on 15 mg/day.
    Summary · context
    A 2-year prophylactic trial was carried out in 31 bipolar manic-depressive subjects, comparing 300 mg/day methylene blue on a double-blind crossover basis with 15 mg/day.
    Summary · context
    All patients were also maintained on lithium.
    Summary · context
    Seventeen patients completed the 2-year trial.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT02380573

Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease

The University of Texas Health Science Center at San Antonion = 117Jul 2015 to Jul 2023

Mild Cognitive Impairment · MCI · Aging · Alzheimer's Disease · AD

Trial pageClinicalTrials.govUpdated 19 Sept 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.